§ 35.100 - Use of unsealed byproduct material for uptake, dilution, and excretion studies for which a written directive is not required.

Copy with citation

Copy as parenthetical citation

Except for quantities that require a written directive under § 35.40(b), a licensee may use any unsealed byproduct material prepared for medical use for uptake, dilution, or excretion studies that is—

Obtained from:

A manufacturer or preparer licensed under § 32.72 of this chapter or equivalent Agreement State requirements; or

A PET radioactive drug producer licensed under § 30.32(j) of this chapter or equivalent Agreement State requirements; or

Excluding production of PET radionuclides, prepared by:

An authorized nuclear pharmacist;

A physician who is an authorized user and who meets the requirements specified in §§ 35.290, or 35.390 and 35.290(c)(1)(ii)(G); or

An individual under the supervision, as specified in § 35.27, of the authorized nuclear pharmacist in paragraph (b)(1) of this section or the physician who is an authorized user in paragraph (b)(2) of this section; or

Obtained from and prepared by an NRC or Agreement State licensee for use in research in accordance with a Radioactive Drug Research Committee-approved protocol or an Investigational New Drug (IND) protocol accepted by FDA; or

Prepared by the licensee for use in research in accordance with a Radioactive Drug Research Committee-approved application or an Investigational New Drug (IND) protocol accepted by FDA.

Previous Section

§ 35.92 - Decay-in-storage.

Next Section

§ 35.190 - Training for uptake, dilution, and excretion studies.